PMID- 33617593
OWN - NLM
STAT- MEDLINE
DCOM- 20210820
LR  - 20210820
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 16
IP  - 2
DP  - 2021
TI  - Association of proangiogenic and profibrotic serum markers with lung function and 
      quality of life in sarcoidosis.
PG  - e0247197
LID - 10.1371/journal.pone.0247197 [doi]
LID - e0247197
AB  - BACKGROUND: Sarcoidosis is a systemic inflammatory granulomatous disease, 
      frequently affecting the lung. If left untreated, it may end in lung fibrosis. 
      Proangiogenic and profibrotic vascular endothelial growth factor (VEGF), 
      transforming growth factor (TGF)-beta1, fibroblast growth factor (FGF)-2 and 
      platelet-derived growth factor (PDGF)-AB are a known therapeutical target in 
      pulmonary fibrosing diseases, e.g. IPF, but there is no targeted therapy option 
      for pulmonary fibrosis in sarcoidosis. OBJECTIVES: The aim of our study was to 
      determine the association of these markers' serum levels on lung function and the 
      patients' quality of life in a long-term follow-up of sarcoidosis patients, to 
      provide further information for finding targeted therapy options for pulmonary 
      sarcoidosis. METHODS: 54 patients with sarcoidosis underwent blood sampling, 
      pulmonary function testing and answered the King's Brief Interstitial Lung 
      Disease (K-BILD) questionnaire at baseline and at three-years follow-up. Serum 
      levels of profibrotic and angiogenic markers were assessed at baseline by 
      enzyme-linked immunosorbent assay. RESULTS: Between 2015 and 2018, 54 patients 
      with biopsy proven sarcoidosis were enrolled. Throughout the observation period, 
      there was a significant decrease in the diffusion capacity for carbon monoxide 
      (DLCO) [%] (-6.5504 +/- 13,39, p = 0.001) and forced expiratory volume in one 
      second predicted (FEV1) [%] (-6.07 +/- 12.09, p = 0.001). Patients with greater 
      impairment of forced vital capacity (FVC) did have significantly higher serum 
      levels of VEGF (p = 0.03) and PDGF-AB (p<0.001). The K-BILD questionnaire did not 
      change significantly during follow-up. However, patients with worsening K-BILD 
      scores did have significantly higher serum-levels of PDGF-AB (2.67 pg/ml +/- 0.93 
      vs. 1.88 pg/ml +/- 0.60, p = 0.004) at baseline, compared to those with unchanged 
      or increasing K-BILD scores. CONCLUSIONS: Among patients with pulmonary 
      sarcoidosis, baseline serum levels of VEGF and PDGF-AB were associated with 
      pulmonary function impairment. Furthermore, PDGF-AB was associated with worsening 
      K-BILD scores. No such association was observed for FGF-2 and TGF-ss1. VEGF and 
      PDGF-AB may be possible prognostic and therapeutic targets in sarcoidosis as a 
      fibrosing ILD beyond IPF.
FAU - Biener, L
AU  - Biener L
AUID- ORCID: 0000-0002-8132-7958
AD  - Department of Internal Medicine II-Cardiology, Pneumology and Angiology, 
      University Hospital Bonn, Bonn, Germany.
FAU - Kruse, J
AU  - Kruse J
AD  - Department of Internal Medicine II-Cardiology, Pneumology and Angiology, 
      University Hospital Bonn, Bonn, Germany.
FAU - Tuleta, I
AU  - Tuleta I
AD  - Department of Cardiology I, University Hospital Muenster, Muenster, Germany.
FAU - Pizarro, C
AU  - Pizarro C
AD  - Department of Internal Medicine II-Cardiology, Pneumology and Angiology, 
      University Hospital Bonn, Bonn, Germany.
FAU - Kreuter, M
AU  - Kreuter M
AD  - Centre for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, 
      University of Heidelberg, Germany and German Centre for Lung Research, 
      Heidelberg, Germany.
FAU - Birring, S S
AU  - Birring SS
AD  - Centre for Human & Applied Physiological Sciences, School of Basic & Medical 
      Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, 
      United Kingdom.
FAU - Nickenig, G
AU  - Nickenig G
AD  - Department of Internal Medicine II-Cardiology, Pneumology and Angiology, 
      University Hospital Bonn, Bonn, Germany.
FAU - Skowasch, D
AU  - Skowasch D
AD  - Department of Internal Medicine II-Cardiology, Pneumology and Angiology, 
      University Hospital Bonn, Bonn, Germany.
LA  - eng
PT  - Journal Article
DEP - 20210222
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Biomarkers)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (platelet-derived growth factor AB)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers/blood
MH  - Female
MH  - Fibroblast Growth Factor 2/*blood
MH  - Fibrosis
MH  - Humans
MH  - Lung/pathology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Platelet-Derived Growth Factor/*analysis
MH  - *Quality of Life
MH  - Sarcoidosis, Pulmonary/*blood/pathology
MH  - Transforming Growth Factor beta/*blood
MH  - Vascular Endothelial Growth Factor A/*blood
PMC - PMC7899331
COIS- The authors have declared that no competing interests exist.
EDAT- 2021/02/23 06:00
MHDA- 2021/08/21 06:00
PMCR- 2021/02/22
CRDT- 2021/02/22 17:12
PHST- 2020/06/20 00:00 [received]
PHST- 2021/02/02 00:00 [accepted]
PHST- 2021/02/22 17:12 [entrez]
PHST- 2021/02/23 06:00 [pubmed]
PHST- 2021/08/21 06:00 [medline]
PHST- 2021/02/22 00:00 [pmc-release]
AID - PONE-D-20-18702 [pii]
AID - 10.1371/journal.pone.0247197 [doi]
PST - epublish
SO  - PLoS One. 2021 Feb 22;16(2):e0247197. doi: 10.1371/journal.pone.0247197. 
      eCollection 2021.